IQV vs. ICLR, INCY, MEDP, CRL, NRC, OABI, ABSI, MXCT, LUNA, and ONMD
Should you be buying IQVIA stock or one of its competitors? The main competitors of IQVIA include ICON Public (ICLR), Incyte (INCY), Medpace (MEDP), Charles River Laboratories International (CRL), National Research (NRC), OmniAb (OABI), Absci (ABSI), MaxCyte (MXCT), Luna Innovations (LUNA), and OneMedNet (ONMD). These companies are all part of the "commercial physical research" industry.
ICON Public (NASDAQ:ICLR) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.
95.6% of ICON Public shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 44.0% of ICON Public shares are held by insiders. Comparatively, 1.6% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
ICON Public has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.
ICON Public presently has a consensus target price of $342.56, indicating a potential upside of 5.46%. IQVIA has a consensus target price of $257.57, indicating a potential upside of 17.56%. Given ICON Public's higher probable upside, analysts clearly believe IQVIA is more favorable than ICON Public.
In the previous week, ICON Public had 1 more articles in the media than IQVIA. MarketBeat recorded 14 mentions for ICON Public and 13 mentions for IQVIA. IQVIA's average media sentiment score of 0.58 beat ICON Public's score of 0.45 indicating that ICON Public is being referred to more favorably in the media.
IQVIA has higher revenue and earnings than ICON Public. IQVIA is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.
IQVIA has a net margin of 9.01% compared to IQVIA's net margin of 8.30%. ICON Public's return on equity of 29.17% beat IQVIA's return on equity.
IQVIA received 37 more outperform votes than ICON Public when rated by MarketBeat users. Likewise, 68.03% of users gave IQVIA an outperform vote while only 65.10% of users gave ICON Public an outperform vote.
Summary
IQVIA beats ICON Public on 10 of the 18 factors compared between the two stocks.
Get IQVIA News Delivered to You Automatically
Sign up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
